The broad public and investors have something in common these days: They don’t have a lot of love for either Tesla or CEO Elon Musk.
Related Posts
Pharma is hopeful about Trump’s second term — here’s what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation and patient access to treatments.
Pentagon chief says ready to ‘fight and win’ against China, urges Asian allies to boost defense spending
While playing up the U.S.’s enduring commitment to the Indo-Pacific region, Hegseth took swipes at the absence of China’s defense minister Dong Jun.
Stock futures are little changed as investors await details on U.S.-China trade policy: Live updates
The S&P 500 inched higher to post its second straight positive session on Monday.